Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug, Oxbryta from worldwide markets. Merck’s MRK Keytruda ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

Awardees were recognized for developing renewable lubricant base oils and ethyl acetate, more environmentally-friendly ...

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

Silicon Valley accelerator Y Combinator held the second Demo Day for its Summer 2024 cohort on Thursday, and just like we saw ...

Summit Therapeutics (SMMT) stock traded lower as Citi downgraded the company to neutral from buy on valuation after recent surge of its shares. Read more here.

Kiran Mazumdar-Shaw accompanied her niece in ringing the opening bell at the Nasdaq headquarters in New York City, marking a ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...